In vitro-Untersuchungen zum Einfluss des SGLT2-Inhibitors Empagliflozin auf LPS-aktivierte Mikroglia vor dem Hintergrund des Morbus Parkinson
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Deutsch
- Notes
-
Kiel, Christian-Albrechts-Universität zu Kiel, Dissertation, 2022
- Keyword
-
Tiermodell
Parkinson-Krankheit
Mikroglia
Entzündung
Nervendegeneration
Zentralnervensystem
Pharmakotherapie
- Event
-
Veröffentlichung
- (where)
-
Kiel
- (who)
-
Universitätsbibliothek Kiel
- (when)
-
2021
- Creator
-
Lenz, Florian
- Contributor
-
Lucius, Ralph-Erich
Leypoldt, Frank
- URN
-
urn:nbn:de:gbv:8:3-2022-00629-5
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lenz, Florian
- Lucius, Ralph-Erich
- Leypoldt, Frank
- Universitätsbibliothek Kiel
Time of origin
- 2021
Other Objects (12)
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Aktivierte Mikroglia triggern Inflammasomaktivierung und lysosomale Destabilisierung in menschlichen Retinalen Pigmentepithelzellen
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Die Bedeutung von Mitogen-aktivierten Proteinkinasen (MAPK) für das Zytoskelett von Mikroglia
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Aktivierte Mikroglia triggern Inflammasomaktivierung und lysosomale Destabilisierung in menschlichen Retinalen Pigmentepithelzellen
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Die Bedeutung von Mitogen-aktivierten Proteinkinasen (MAPK) für das Zytoskelett von Mikroglia
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Aktivierte Mikroglia triggern Inflammasomaktivierung und lysosomale Destabilisierung in menschlichen Retinalen Pigmentepithelzellen
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Die Bedeutung von Mitogen-aktivierten Proteinkinasen (MAPK) für das Zytoskelett von Mikroglia
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury